相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Daratumumab induces mechanisms of immune activation through CD38+NK cell targeting
Domenico Viola et al.
LEUKEMIA (2021)
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA
Giovanni Palladini et al.
BLOOD (2020)
TGF-β1-Licensed Murine MSCs Show Superior Therapeutic Efficacy in Modulating Corneal Allograft Immune Rejection In Vivo
Kevin Lynch et al.
MOLECULAR THERAPY (2020)
Targeting of CD163+Macrophages in Inflammatory and Malignant Diseases
Maria K. Skytthe et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity
Austin P. Huffman et al.
JCI INSIGHT (2020)
Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma
Dawn Swan et al.
HEMASPHERE (2020)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
The Two Faces of Tumor-Associated Macrophages and Their Clinical Significance in Colorectal Cancer
Marta L. Pinto et al.
FRONTIERS IN IMMUNOLOGY (2019)
A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma
Michael Sebag et al.
BLOOD (2019)
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study
M. O'Dwyer et al.
BLOOD ADVANCES (2019)
Macrophages as regulators of tumour immunity and immunotherapy
David G. DeNardo et al.
NATURE REVIEWS IMMUNOLOGY (2019)
The Human FcγRII (CD32) Family of Leukocyte FcR in Health and Disease
Jessica C. Anania et al.
FRONTIERS IN IMMUNOLOGY (2019)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy
Andre Veillette et al.
TRENDS IN IMMUNOLOGY (2018)
Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies
Praful Ravi et al.
BLOOD CANCER JOURNAL (2018)
Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer
Grace O'Malley et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Targeting macrophages: therapeutic approaches in cancer
Luca Cassetta et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
CD32 Ligation Promotes the Activation of CD4(+) T Cells
Maria Pia Holgado et al.
FRONTIERS IN IMMUNOLOGY (2018)
Is immunotherapy here to stay in multiple myeloma?
Paula Rodriguez-Otero et al.
HAEMATOLOGICA (2017)
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Jennifer L. Guerriero et al.
NATURE (2017)
C-C Chemokine Ligand-5 is critical for facilitating macrophage infiltration in the early phase of liver ischemia/reperfusion injury
Chiou-Mei Lee et al.
SCIENTIFIC REPORTS (2017)
Is immunotherapy here to stay in multiple myeloma?
Paula Rodriguez-Otero et al.
HAEMATOLOGICA (2017)
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
Tineke Casneuf et al.
BLOOD ADVANCES (2017)
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma
Inger S. Nijhof et al.
BLOOD (2016)
High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma
Hua Wang et al.
BRITISH JOURNAL OF CANCER (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma
Yi Li et al.
ONCOTARGET (2015)
Targeting the bone marrow microenvironment in multiple myeloma
Yawara Kawano et al.
IMMUNOLOGICAL REVIEWS (2015)
Targeting colon cancer cell NF-kappa B promotes an anti-tumour M1-like macrophage phenotype and inhibits peritoneal metastasis
A. E. Ryan et al.
ONCOGENE (2015)
Curing myeloma at last: defining criteria and providing the evidence
Bart Barlogie et al.
BLOOD (2014)
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
Carola H. Ries et al.
CANCER CELL (2014)
Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy
Christian P. Pallasch et al.
CELL (2014)
THP-1 cell line: An in vitro cell model for immune modulation approach
Wasaporn Chanput et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2014)
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy
Nuray Gul et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Macrophage cytokines: involvement in immunity and infectious diseases
Guillermo Arango Duque et al.
FRONTIERS IN IMMUNOLOGY (2014)
The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer
Ross Stewart et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Tumor Promotion by Intratumoral Plasmacytoid Dendritic Cells Is Reversed by TLR7 Ligand Treatment
Isabelle Le Mercier et al.
CANCER RESEARCH (2013)
Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
Sanne J. de Haart et al.
CLINICAL CANCER RESEARCH (2013)
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
James D. Mellor et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
The use of THP-1 cells as a model for mimicking the function and regulation of monocytes and macrophages in the vasculature
Zhenyu Qin
ATHEROSCLEROSIS (2012)
Myeloma as a model for the process of metastasis: implications for therapy
Irene M. Ghobrial
BLOOD (2012)
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Differential macrophage programming in the tumor microenvironment
Brian Ruffell et al.
TRENDS IN IMMUNOLOGY (2012)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
The Immune Microenvironment of Myeloma
Kimberly Noonan et al.
CANCER MICROENVIRONMENT (2011)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
CCL5 as an adjuvant for cancer immunotherapy
Natalia Lapteva et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis
Yuhuan Zheng et al.
BLOOD (2009)
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, and FcγRIV
Veronique Minard-Colin et al.
BLOOD (2008)
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism
Evdoxia Hatjiharissi et al.
BLOOD (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
The PD-1-PD-L pathway in immunological tolerance
T Okazaki et al.
TRENDS IN IMMUNOLOGY (2006)
Distinct role of macrophages in different tumor microenvironments
CE Lewis et al.
CANCER RESEARCH (2006)
分享论文
